# Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

> **NCT03942224** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 49 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT03942224
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-03
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942224, "Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03942224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*